QurAlis Invited to Present at 44th Annual J.P. Morgan Healthcare Conference
QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has been invited to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 8:30AM PT at the Westin St. Francis in Elizabethan Room D.
QurAlis to Present Data From its Phase 1 Clinical Trial of QRL-101, a Potential Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener, at American Epilepsy Society 2025 Annual Meeting
QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that data from the company’s Phase 1 proof-of-mechanism clinical trial of QRL-101, a potentially best-in-class selective Kv7.2/7.3 ion channel opener, were selected for a poster presentation at the American Epilepsy Society (AES) 2025 Annual Meeting being held December 5-9, 2025 in Atlanta, GA.
QurAlis to Participate in Piper Sandler 37th Annual Healthcare Conference
QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will present a company update at the Piper Sandler 37th Annual Healthcare Conference. Dr. Roet’s presentation is Tuesday, December 2, 2025 at 1:40PM ET. Management will also participate in one-on-one investor meetings.
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer
QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has appointed Manoj Malhotra, M.D., as chief medical officer (CMO).
QurAlis to Participate in Upcoming Investor Conferences in November
QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will participate at the following investor conferences in November. Management will also participate in one-on-one investor meetings.
QurAlis to Participate in Upcoming Investor Conferences in September
QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will participate at the following investor conferences in September. Management will also participate in one-on-one investor meetings.
QurAlis Announces New Global Headquarters
QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced the opening of its new global corporate headquarters in Cambridge, MA. The company’s new 30,000 square foot state-of-the-art research facility and office space located at 35 Cambridgepark Drive (“35 CPD”), doubles QurAlis’ footprint in the heart of Cambridge’s vibrant Alewife Biotech Park.
QurAlis Announces Exclusive License on Novel Mechanism for Fragile X Syndrome (FXS) to Enable Development of First Potential Disease-Modifying Therapy
QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced it has entered into an exclusive license agreement with UMass Chan Medical School (“UMass Chan”) on a novel RNA-targeted mechanism confirmed to restore functional protein for Fragile X syndrome (FXS).
QurAlis Boosts World-Class Leadership Team With Addition of Three New Members
QurAlis Corporation, a biotech company developing breakthrough precision medicines for ALS and other genetically validated neurodegenerative diseases, today announced the appointment of three new members to the leadership team, deepening expertise in corporate development, operations, project management, and accounting.
Cell Reports Publishes Discovery Data Supporting the Importance of Ion Channel, Kv7.2/7.3 as a Therapeutic Target in ALS
QurAlis Corporation, a biotech company developing breakthrough precision medicines for ALS and other genetically validated neurodegenerative diseases, today announced the publication of an article in Cell Reports titled Human Amyotrophic Lateral Sclerosis Excitability Phenotype Screen: Target Discovery and Validation by QurAlis founders Kasper Roet, Ph.D., Clifford Woolf, M.D., Ph.D., and Kevin Eggan, Ph.D., who pioneered a high-content, live-cell imaging screen using ALS patient-derived motor neurons in combination with a compound library generated by Pfizer to identify drug targets to treat hyperexcitability induced neurodegeneration in ALS patients.
